This course is part of the Employing Innovation and Overcoming Inertia: New Options in Basal Insulin curriculum.
Clinical Coffee Break
0.50 CME Credit
Switching Basal Insulins in the Patient with T2DMAn Interactive Video Experience This course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com
In this short Clinical Coffee Break, expert faculty explore the all-too-common case of a patient with type 2 diabetes mellitus on basal insulin for many years but still struggling with adherence, hypoglycemia, and weight loss. You will explore how a second-generation basal insulin may be the answer for this patient. Most important, you’ll walk away with practical tips and communication strategies to help you and the patient overcome barriers to insulin adjustments and avoid therapeutic inertia.
0.50 AMA PRA Category 1 Credits, 0.50 ABIM MOC or 0.40 AANP, including 0.40 AANP Pharm
Release Date: 10/14/2022
Expiration Date: 10/14/2023
- Appraise the clinician barriers that can slow or prevent the initiation and/or intensification of basal insulin therapy for people with type 2 diabetes mellitus (T2DM)
- Identify patients who could benefit from newer long-acting basal insulins
- Outline communication strategies to overcome patient barriers to insulin use and adherence
Michelle F. Magee, MD, MBBCh, BAO, LRCPSI
MedStar Health Diabetes Institute
Professor of Medicine
Georgetown University School of Medicine
Jay H. Shubrook, DO, FAAFP, FACOFP
Primary Care Department
Touro University College of Osteopathic Medicine
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Michelle F. Magee, MD: Researcher for Novo Nordisk and Uluru.
Jay H. Shubrook, DO, FAAFP, FACOFP: Advisor for Abbott, AstraZeneca, Bayer, Eli Lilly, Nevro, and Novo Nordisk. Consultant for Abbott, Bayer, and Novo Nordisk.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
AMA PRA Category 1 Credits
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Pri-Med Institute designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pri-Med Institute is accredited by the American Association of Nurse Practitioners® as an approved provider of nurse practitioner continuing education. Provider number: 040308.
This activity is approved for 0.40 contact hours of continuing education, which includes 0.40 hours of pharmacology.
MOC Credit Information
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Supporters and Partners
Novo Nordisk Inc.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients. Data, indications, and guidelines presented in this activity are current as of the activity release date and they are subject to change as new information is published.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email email@example.com or call (877) 477-4633.